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Abstract   
Hepatitis B virus (HBV) infection is a major public health problem and its outcome depends on the kinetics of 
the virus host interaction and in particular on the strength of the immune response.this study was done to 
illustrate some immunological in vaccinees and effectiveness of HBV vaccine in vaccinees groups . This study 
was conducted from September , 2011 to October, 2012 .   ELISA  assay was used for detection  of  hepatitis B 
virus surface antigen  as well as  IgM- anti hepatitis  B-core antigen  . This study was also include measurement 
of anti- HBsAg level  to detect the immune response in vaccinees  . It was found that significant differences in 
the antibodies levels  according to post vaccination periods  and the highest antibodies level in male and female 
was reached after 90 days post 3rd dose of vaccination , it was  124.85 mIU/ml and 155.94 mIU/ml in male and 
female respectively.  There was also significant differences in (IL-2 it was found that the highest level of IL-2 
was reached  27.21 pg/ml and 33.94 pg/ml  90 days post 3rd dose  of vaccination in male and female respectively.   
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1.Introduction 
The term (Hepatitis) is applied to a broad category of clinical, pathologic conditions, charcterized histologically 
by hepatocellular necrosis and inflammatory cell infiltration of the liver ( Pondei & Ibrahim  2013). Hepatitis 
results from hepatocyte damage produced by the action of varing form of chemical agents, including, drugs, 
toxins, alchohol or some pathogens such as, viruses and others (Tannapfel etal. 2011). However, virus still 
represents the most common and important causative agent of hepatitis  caused by at least five different viruses 
which are ecologically, immunologically, and epidemiologically distinct , Viral hepatitis types are: A (formerly 
called infectious hepatitis), B (serum hepatitis), C (formerly called post-transfusion non-A  non-B hepatitis), D 
(Delta hepatitis), E (Enterically transmitted). F and G, cryptogenic (caused by a virus as yet unidentified), (Das 
&Maini  2010 )  .  
HBV is structurally complex that it belongs to a group of animal viruses known as Hepadnaviridae. It is 42 nm in 
diameter and consists of two primary components: a DNA, viral core and an outer protein coat ( Locarnini & 
Zoulim 2010). The viral core represents the infectious part of the virus and the outer coat carries the major 
antigenic determinant of the virus, the HBsAg. The viral core rests within the nucleocapsid of the virus. It is 
approximately 27 nm in diameter and contains partially double stranded DNA , DNA polymerase , a core antigen 
(HBcAg) , and an  e   antigen (( Pondei & Ibrahim  2013). 
 The outer coat of the virus consists of varied combinations of proteins and includes the important, yet non-
infectious, surface antigen (HBsAg). Most of the excess, non-infectious protein (HBsAg) is released into the 
blood stream in the form of 22 nm spherical particles and filaments of the same diameter with variable length up 
to 200 nm(Tiollais There are four major subtypes of HBsAg (adw , adr , ayw  and ayr) having a group specific  
determinants (a), shared by all HBsAg and type specific sub-determinants d, y, w, and r and several further 
categories of subtypes, named adw2 , adw4 , ayw3 , ayw4 (   Kondo etal. 2013   ) 
Vaccination was the most effective strategy for control and eradication of HBV infection and it has been one of 
the great technical development contributing to the freedom from life-threatening infectious disease , 
Hepatitis B vaccine have been commercially avaliable since 1982, it consists of a small protein from the surface 
of the hepatitis B virus called Hepatitis B surface antigen (HBsAg). The first HB vaccine was manufactured by 
the purification and inactivation of HBs Ag obtained from the plasma of chronic hepatitis B virus carriers called  
Plasma Derived Vaccine  (Faas etal.  2011) . 
HBV vaccine should  be administred in deltoid muscle of adults, adolescents and children or in the anterlateral 
thigh  muscle of neonates, infants and chlidren in the second years of life in three doses at intervals of (0 , 1 and 
6 months) ,All Licensed formulation for both vaccine produce high rate (95%) of protective antibody (Anti-HBs 
Ab > 10 mIU/ml) when complete vaccine doses ( Ryckman etal. 2010). The availability of high safe and 
effective hepatitis B vaccines now makes possible the establishment of programs aimed at eventual elimination 
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of HBV  as a disease in man and the prevention of the first human cancer by a program of immunization. World 
wide strategies for hepatitis B prevention will differ from area to area according to the epidemiology of HBV 
infection(Faas etal.  2011) . 
People with risk factors for HBV infection should be vaccinated by using the age appropriate vaccine dose and 
schedule ,these include people at accupation risk of infection through exposure to blood or blood products they 
including Health Care Workers (Laboratory technicians, Dentistry, Surgeon, Nursing and other), medical 
students, house hold contact to HBV carriers ,users of illicit drugs, Hemodialysis patients, Insulin Dependent 
Diabetes Mellitus IDDM  patients,infant born to HBsAg positive mothers, clients staff of instutions for the 
developmentally disable, recipients of certaine blood products such as clotting factors and international travelers 
especially in area with high or intermediate of HBV infection (Alkandari etal. 2013). 
 
2.Samples Collection and Processing  
Total of  (20) unvaccinated healthy individuals (10) female and ( 10) male  at age group between  ( 20-21) years  
were tested for HBsAg , anti-HBcAg , anti-HBsAg and estimation of certain cytokine levels (IL-2) before and 
after vaccination for estimation  effectiveness of HBV vaccine in vaccines group .  Vaccination by using 
(EUVAX-B) (LG, Korea),   . Determination of anti-HBs antibodies after complete the vaccination program (If 
anti-HBsAb ˂ 10 mIU/ml  was considered as non responders) While Anti- HBsAb ≥ 10 mIU/ml was considered 
as responders.                                                                                        
Twenty control group un vaccinated. Blood sample of 5ml were obtained from each subject by using sterile 
syringes. Each blood sample was collected in sterile plan tube , labeled then all samples were incubated at room 
temperature till clotted. The serum was separated from collected blood by centrifugation in Kokusan (Japan) , 
centrifuge at 3000 r.p.m for 10 min. and transferred into labeled tube (3tube of each subject) each tube contain 
100mµ  . Each sample was tested for HBsAg detection ( ACON company, USA) ,anti- HBcAg ( Biokit 
company, Spain) , anti-HBsAg (Biokit company, Spain)   as well as IL-2 test ( eBioscience company, USA). 
only cases of negative result for all HBV markers were vaccinated. The study include twenty healthy subject a  
Control group.                                                                                                                         
Euvax B is given only by intramuscular rout .    
 ●     In pediatric (children aged up 5 to 15 years of age) the dose was 0.5 ml containing 10 Mg of HBsAg.  
 ●    In adult (from 16 years and up old the dose was 1.0 ml containing 20 Mg of HBs Ag). While in   
        hemodialysis patients the vaccine dose was double containing 40 Mg of HBs Ag. 
                                                                
3.Statistical Analysis  
Data were analyzed statistically using complete randomized design(CRD), LSD and X2 test (Naizi 2004).  
 
4.Results and Discussion  
4.1 Virological antigen test. 
 The results of virological antigen  diagnosis for subjects  before vaccination  shows negative result for each 
HBsAg,anti- HBsAg  and anti-HBcAg. Table (1) show diagnosis of virological antigen for subjects  before 
vaccination. 
 
















10 10 10 10 male 
10 10 10 10 Female  
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Precedent studies show that necessary detection of  anti- HBcAg  for subjects before  vaccination for 
confirmation that immune against hepatitis B virus cause by vaccine not infection , also anti-HBcAg test using to 
detection recent and old infection because anti-HBcAg still for life (Hall 2010). Antibodies of hepatitis B surface  
antigen appear during infection or vaccination (Passos et al. 2011).  
 
Table (2) show value of titer for IL-2 in vaccinees  before vaccination for use  this value for comparative with 
IL-2 result after vaccination.  
 
Table 2. Constration of IL-2 cytokine in sera of sera of vaccinees before HBV vaccination 








Test of IL-2 cytokine for subjects before vaccination show don’t  increased in concentration of IL-2 .  Titer of 
IL-2 cytokine different before and after vaccination , level of IL-2 is lower in sera of subjects before vaccination 
than these after vaccination (Jincheng etal. 2011).                                              
 4.2 Titer of Anti-HBsAg  of vaccinated  after vaccination                                                           
 Detection of anti- HBsAg by using ELISA  assay show significant differences in the antibodies level according 
to post vaccination period and the highest antibodies level in male was reached after 90 days post 3rd 
 
dose of 
vaccination , it was 124.85mIU/ ml . female shows highest antibodies level after 90 days post 3rd 
 
dose of 
vaccination , it was 155.94 mIU/ ml. While  the period 14, 21 and 28 day  don’t show any immune response in 
male, because titer of antibodies was reached to 2.70 mIU/ ml, 6.70 mIU/ ml and 8.41mIU/ ml respectively 
whereas in female the period 14 and 21 day don’t show any immune response because titer of antibodies was 
reached to 2.83 mIU/ ml and 7.62mIU/ ml respectively . Result shows  significant differences comparative with 
unvaccinated control group     (P< 0.05). table ( 3).    
 
Table 3. concentration of anti-HBs in sera of vaccines after HBV vaccination. 
 
Level of anti-HBs (mIU/ ml) M±SD  subjects  dose  sex  
Period ( days)  post vaccination   
90day  60day  28day  21day  14day  
0 0  0  0  0  control First male 
24.23±14.14  17.19±11.30  9.29± 8.41 6.70± 4.75 2.70± 1.39  patient 
0  0  0  0  0  control Second 
58.20±40.50  50.09±34.08  37.62±24.89  29.06±17.17  26.70± 15.59  patient 
0  0  0  0  0  control Third 
 124.85± 55.69  100.28± 56.34  86.40± 58.90  79.82± 57.31  68.72± 49.58  patient 
0  0  0  0  0  control First  female 
11.62±4.17 10.70± 3.83  10.46 ± 2.98  7.62± 2.30  2.83± 1.93  patient 
0  0  0  0  0             control    Second  
57.94± 39±40  41.03±31.88  25.90±19.02  18.52±13.90  13.32±7.45  patient 
0  0  0  0  0  control Third  
155.94± 59.25  130.65±54.25  90.04± 53.36  88.12± 53.01  81.74±47.66  patient 
LSD(0.05)= 18.261 
 
* Significant differences (p˂0.05).                                                                                                                                                                     
 
Concentration (pg/ml)     M±SD          Cytokine 
Male  female 
1.32± 0.15 2.61± 1.38 IL-2 
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Efficacy of vaccination is determined by assessment of the level of antibodies to HBsAg ( Faas etal. 2011). A 
serum level of at  least 10mIU/ ml of anti-HBs antibodies reached after vaccination  has been proposed to be the 
lowest limit for protection ( Central for Disease Control and Prevention  2006). However , a small group of 
vaccinees  produce no (<10mIU/ ml) or suboptimal concentration (10-100mIU/ ml) of antibodies which are 
known as non-responders and low – responders ( Ertem etal. 2010).   The reason for non- and hypo – 
responsiveness are unclear yat and may involve multiple factors including dose and procedures of vaccination , 
recipientʼs  age , gene background , immune response ( Jincheng etal. 2011).    
 
 
The study also include measurement of IL-2 cytokine by using ELISA assay. Results shows elevation level of 
IL-2 in sera of vaccination subjects .The highest level  of IL-2 in male occur after 90 day post each dose it was 
reached to 11.58 pg/ml, 21.12 pg/ml and 27.21pg/ml respectively . The highest level  of IL-2 in female occur 
after 90 day post each dose it was reached to 13.82 pg/ml, 28.88 pg/ml and 33.94pg/ml respectively . Result 
shows  significant differences comparative with unvaccinated control group (P< 0.05). table (4).   
 
Table 4. concentration of IL-2 (Pg/ml) in sera of vaccines after HBV vaccination 
Level of IL -2 (pg/ml) M±SD subjects dose sex 
Period ( days)  post vaccination  
90day 60day 28day 21day 14day 7day 
1.50±0.26 1.62±0.26 1.56±0.25 1.39±0.30 1.46±0.23 1.37±0.12 control First male 
11.58±1.45 11.25±3.12 10.42±1.04 8.62±3.09 8.05±2.63 6.38±1.07 patient 
1.59±0.34 2.14±0.68 2.13±0.25 1.56±0.49 1.56±0.11 1.72±0.15 control Second 
21.12±8.41 20.07±1.57 17.80±4.99 17.01±24.16 15.01±10.50 13.04±9.30 patient 
1.85±0.72 2.16±0.81 2.01±0.41 1.99±0.53 1.87±0.87 1.86±0.36 control Third 
 27.21±25.37 25.12±5.56 23.83±14.56 23.08±0.78 23.01±1.12 21.53±20.57 patient 
1.54±0.25 1.34±0.26 1.51±0.19 1.52±0.25 1.52±0.23 1.65±0.32 control First female 
13.82±0.97 11.29±0.93 10.98±1.49 10.34±12.57 7.38±1.76 4.94±3.33 patient 
1.94±0.49 1.75±0.64 1.89±0.52 1.83±0.54 1.87±0.78 1.78±0.51 control Second 
28.88±2.44 25.69±15.36 21.39±9.77 20.37±1.59 18.27±1.42 18.37±16.39 patient 
2.10±0.53 1.85±0.67 1.87±0.51 1.82±0.49 1.97±0.44 1.98±0.46 control Third 
33.94±8.33 32.22±13.78 30.29±14.71 30.08±9.61 27.39±10.23 28.95±0.75 patient 
LSD(0.05)= 7.305 
* Significant differences (p˂0.05)   
Cytokines act as a key role in the regulation of the immune response to hepatitis B vaccine. The present study 
analyzed the serum level of IL-2 as indicator of immune response to vaccination in different group. T–helper 
cells (Th) can be functionally distinguished based on the profile of cytokine production. Th1 cells induce cell 
mediated immune response by secreting cytokines such as IL-2. On the other hand, Th2–cells secrete some other 
cytokines such as IL-4, IL-5,  IL-10 and IL-13 seems to be essential for antibody production against HBV 
vaccine ( Dowlati etal. 2010). Humoral and cellular immune response against hepatitis B virus antigen are 
responsible for clearance of the virus and destruction of infected cells leading to possible curing of infected 
hepatocytes (FitzSimon etal. 2013)  . Vaccination with HBsAg induces a protective immunity through Th cell 
dependent on anti HBs antibody production usually subpopulation of T–cells are probably acting as a central role 
in response to HB vaccine.(Passos etal. 2011).                    
 
Conclusion 
• Anti- HBsAg titer in sera of female who received HBV vaccine is higher titer than male . 
• IL-2 titer in sera of vaccination subjects is higher titer than control group  
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• Immune response in female more than male  
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